Pacific Biosciences (DE:P09)
NASDAQ:P09
Earnings Data
Report Date
Aug 05, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.11Last Year’s EPS
-0.12Same Quarter Last Year
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presented a mixed picture: strong commercial and strategic progress in consumables, clinical adoption, SPRQ-Nx beta success, and a major Basecamp collaboration, alongside meaningful near-term headwinds including flat total revenue, a decline in instrument revenue, gross margin pressure from rising compute costs and promotional ASP compression, and a modest downward revision to guidance. Operational improvements (lower operating expenses, improved non-GAAP net loss) and strategic actions bolster the long-term outlook, but near-term revenue and margin challenges temper enthusiasm.Company Guidance
Record Consumable Revenue (Third Consecutive Quarter)
Consumable revenue reached a record $21.8M in Q1 2026, up 9% year-over-year from $20.1M, marking the third consecutive record quarter for consumables.
Clinical Consumable Shipments More Than Doubled
Shipments to clinically focused accounts grew greater than 100% year-over-year; clinical shipments now represent a mid-teens percentage of total consumable shipments, roughly double versus prior year.
Revio Pull-Through and System Demand
Annualized Revio pull-through per system was approximately $229,000 (within the expected $225k–$250k range). Revio shipments increased to 15 units in Q1 (vs. 12 in Q1 2025) and cumulative Revio shipments reached 346 systems.
Vega Installed-Base Expansion
27 Vega systems shipped in Q1 (vs. 28 in Q1 2025); more than 85% of Vega placements went to new customers this quarter, expanding HiFi reach and adoption.
EMEA Outperformance
EMEA revenue grew 17% year-over-year to $10.8M, driven by consumables demand and clinical account expansion as customers move from validation to production.
Strategic Portfolio Actions Strengthened Balance Sheet
Sale of high-throughput short-read assets to Illumina generated approximately $48.1M in net cash proceeds and the company also resolved outstanding litigation, sharpening focus on long-read sequencing.
Major AI/Scaling Collaboration with Basecamp Research
Signed collaboration to deeply sequence ~100,000 metagenomic samples (Trillion Gene Atlas project), the largest PacBio HiFi project to date, positioning HiFi for large-scale AI/biology model training.
SPRQ-Nx Beta Results and Near-Term Commercial Launch
SPRQ-Nx beta customers reported double-digit yield improvements and multi-use SMRT Cell capability (3x); full commercial launch expected later in the month and SPRQ-Nx planned for Vega later this summer, expected to improve economics and throughput.
Operating Expense Reduction
Non-GAAP operating expenses decreased 19% year-over-year to $49.9M in Q1 2026 from $61.7M in Q1 2025; noncash share-based compensation declined to $3.8M from $8.0M.
Improved Non-GAAP Net Loss
Non-GAAP net loss improved to $35.9M ($0.12 per share) in Q1 2026 from $44.4M ($0.15 per share) in Q1 2025, indicating progress toward narrowing losses.
DE:P09 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:P09 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | €1.46 | €1.23 | -15.70% |
Feb 12, 2026 | €1.50 | €1.51 | +0.67% |
Nov 05, 2025 | €1.77 | €1.42 | -19.59% |
Aug 07, 2025 | €1.17 | €1.16 | -0.26% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Pacific Biosciences (DE:P09) report earnings?
Pacific Biosciences (DE:P09) is schdueled to report earning on Aug 05, 2026, TBA (Confirmed).
What is Pacific Biosciences (DE:P09) earnings time?
Pacific Biosciences (DE:P09) earnings time is at Aug 05, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Pacific Biosciences stock?
The P/E ratio of Pacific Biosciences is N/A.
What is DE:P09 EPS forecast?
DE:P09 EPS forecast for the fiscal quarter 2026 (Q2) is -0.11.